AstraZeneca PLC (LON: AZN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 187.68B |
| Revenue (ttm) | 37.70B |
| Net Income (ttm) | 5.01B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.21 |
| PE Ratio | 37.75 |
| Forward PE | 18.52 |
| Dividend | 2.40 (1.98%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 81,627 |
| Open | 12,234 |
| Previous Close | 12,106 |
| Day's Range | n/a |
| 52-Week Range | 9,461 - 12,704 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 25, 2024 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial numbers in USD Financial StatementsNews
Here are Big Pharma’s leading blockbuster makers
Eli Lilly (LLY) and AstraZeneca (AZN) top the list of companies with the most blockbusters approved in 2014-2023, according to analytics firm Evaluate. Read more here.
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
AstraZeneca has unveiled plans to become the dominant global presence in breast and lung cancer markets. Click here for my Q2 earnings release preview.
These Stocks Offer Gains Without the U.S. Political Drama
Keir Stamer's style is the polar opposite of Donald Trump. Many wondered if he was too boring to be U.K. Prime Minister.
Companies Reporting: Coca-Cola, easyJet, AstraZeneca
Coca-Cola, easyJet, AstraZeneca are amongst the FTSE 350 and other selected companies reporting earnings for the week of 22 July 2024
Evaluating Merck & Co Against Peers In Pharmaceuticals Industry
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comp...
AstraZeneca Closes Acquisition of Amolyt Pharma
LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrin...
Safety concerns behind Hong Kong abandoning AstraZeneca’s Covid-19 vaccines, new book says
In My Life in Medicine: A Hong Kong Journey, Professor Yuen Kwok-yung sheds light about his time as a government adviser during Covid.
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Labour Party member Keir Starmer is set to become the new prime minister of the United Kingdom with a win over the Rishi Sunak -led Conservative Party. The win marks an end to 14 years of Conservative...
AstraZeneca expands its Chennai office
AstraZeneca India expands its Chennai office with a focus on AI, data science, and supply chain analytics for healthcare, accommodating 1,300 employees. Learn more about the expansion here!
AstraZeneca expands its Chennai office, making its biggest GCC globally
CHENNAI: AstraZeneca India, the global capability centre (GCC) of British- Swedish pharmaceutical company AstraZeneca, on Thursday announced expansion.
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
The Federal Trade Commission (FTC) has initiated an investigation into Teva Pharmaceutical Industries Ltd (NYSE: TEVA) over its refusal to remove about two dozen patents for its asthma and COPD inhal...
AstraZeneca COVID prevention antibody gets EU fast-track review
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated asses...
Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
Insights Into Eli Lilly and Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive ...
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
On Wednesday, China approved AstraZeneca plc's (NYSE: AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with loc...
Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines
KIRKLAND, Wash.--(BUSINESS WIRE)--Tanium today shared the success story of customer AstraZeneca in securing over 125,000 endpoints across 125 countries using the Tanium XEM platform.
AstraZeneca’s Tagrisso with chemo approved in China for lung cancer
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company s...
AstraZeneca's Oncology Success: Fueling Future Growth
AstraZeneca is becoming a leader in the cancer therapeutics market, that's reflected in the growth of its share price. See why AZN stock continues to be a buy.